News

Royalty Pharma and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the company has

Updates 2019 full-year financial guidance Conference call with slides to be held today at 5:00 p.m. Eastern time SAN DIEGO and NEW YORK (March 5, 2019) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma  announce the sale of Ligand’s Promacta®-related intellectual property

Royalty Pharma announced today that it has acquired future royalty streams and $85 million of potential commercial milestones on Sanofi’s (NYSE:SNY) Soliqua® 100/33/ Suliqua® and Lyxumia®/Adlyxin® from Zealand Pharma A/S (NASDAQ:ZEAL), for $205 million in cash, to be paid when the transaction

Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million. Royalty Pharma acquires approximately 2% royalty rights on global annual net sales of rimegepant and BHV- 3500 from Biohaven for $100 million. Royalty participation rate subject to reduction to

Royalty Pharma Acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU132) Across All Indications for $175 Million. Royalty Pharma Acquires $75 Million of Immunomedics Common Stock at $17.15 per share, a More Than 15% Premium over 15-Day Moving Average.

Dublin, Ireland and New York, NY (US) – February 27, 2017  — Perrigo Company plc (NYSE; TASE: PRGO) today announced it has signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri® (natalizumab) to Royalty Pharma.

Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 Million Plus $10 Million Equity in Cytokinetics. Cytokinetics Agrees to Exercise Option to Co-Fund Phase 3 Development Program Under Collaboration with Amgen for Increased Royalty and Co-Promotion Rights in North America New York,

Proceeds will fund research and scholarships; will also be shared with inventors. Los Angeles, CA (US) and New York, NY (US) – March 4, 2016  — UCLA and Royalty Pharma announced today that UCLA has sold its royalty interest connected with a leading prostate cancer medication, Xtandi, whose

Largest pharmaceutical royalty purchase ever completed. Funds will be used to expand cystic fibrosis research, care and patient programs. New York, NY (US) – November 19, 2014  — Royalty Pharma announced today its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned

Jim Reddoch, PhD, Royalty Pharma Executive Vice President for Research and Investments Joins Avillion Board. London (UK) and New York, NY (US) – May 6, 2014  — Avillion LLP, a company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development